Abstract:Objective: To explore the clinical features and treatment of pyoderma gangrenosum (PG). Methods: A retrospective observational study was conducted. From January 2012 to July 2021, 25 patients with PG who met the inclusion criteria were admitted to Beijing Fucheng Hospital, including 16 males and 9 females, with the age of onset of disease being 14 to 75 years. Among them, the classification of PG identified 17 cases of ulcerative type, 6 cases of pustular type, 1 case of proliferative type, and 1 case of bullous type. Six patients were accompanied with systemic diseases, while 19 patients were not accompanied with systemic diseases. At the same time of systemic treatment with glucocorticoids, dressing changes or surgical skin grafting was performed on the wounds. The results of laboratory and histopathological examinations, the overall curative effects and follow-up of patients, the wound healing time of patients with negative and positive microbial culture results of wound secretion specimens, and the curative effects of patients with and without systemic diseases were analyzed. Results: The results of blood routine examination of 19 patients were abnormal, and all the immunological indexes were normal in all the patients; the microbial culture results of wound secretion specimens were positive in 14 patients; and the histopathological examination results of ulcer boundary tissue in 15 patients with rapid wound progress were mainly local tissue inflammatory changes. The wounds were cured in 17 patients, mostly healed in 7 patients, and not healed in 1 patient. After one-year's follow-up, the PG in 3 patients relapsed due to self-discontinuation of medication after discharge, and the wounds were healed gradually after adjustment of medication, while the remaining patients had no relapse. The days of wound healing in 14 patients with positive microbial culture results of wound secretion specimens were 21-55 days, and the days of wound healing in 11 patients with negative microbial culture results in wound secretion specimens were 20-54 days. In the 6 patients with systemic diseases, the wounds of 3 patients were cured, and the wounds of the other 3 patients were mostly healed. In the 19 patients without systemic diseases, the wounds of 14 patients were cured, the wounds of 4 patients were mostly healed, and the wound of 1 patient was not healed. Conclusions: The laboratory examination and pathological manifestations of patients with PG lacks characteristics, and their clinical manifestations are rich and diverse, thus PG can be easily misdiagnosed. The glucocorticoids combined with immunosuppressive therapy have good effects on PG. Surgical intervention can be performed on the wounds. Specifically, excessive debridement is not recommended in the acute phase, but skin grafting can be performed in the contraction phase.

Utility of a synthetic hybrid-scale fiber matrix in the management of pyoderma gangrenosum: a case study

Non-surgical Management of Complex Refractory Pyoderma Gangrenosum With Negative Pressure Wound Therapy With Instillation

Local wound care management for pyoderma gangrenosum

Clinical, epidemiological, and therapeutic hallmarks of pyoderma gangrenosum: a case series of 35 patients

Pyoderma Gangrenosum and Systemic Treatment

Clinical application of a synthetic hybrid-scale fiber matrix in a pediatric trauma patient

Clinical management of pyoderma gangrenosum

The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives

[Analysis of clinical features and treatment of pyoderma gangrenosum].

Practical aspects of the diagnosis and management of pyoderma gangrenosum

Multiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report

Successful Treatment of Pyoderma Gangrenosum With Composite Grafting of Acellular Dermal Matrix and Glycerolized Skin: A Preliminary Experience

Utility of synthetic electrospun fiber matrix in general surgery: From head to toe

Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials.

Pyoderma gangrenosum complicated with hematological malignancies: Two case reports

A Multicenter Clinical Trial of Recombinant Human GM-CSF Hydrogel for the Treatment of Deep Second-Degree Burns.

Wound Healing Outcomes Following Treatment With Synthetic Hybrid-Scale Fiber Matrix After Resection of Soft Tissue Tumors or Infections

Clinicopathological Profile of Pyoderma Gangrenosum: A 10-Year Retrospective Study from a Tertiary Care Center in South India

Pyoderma Gangrenosum: Treatment Options

Janus kinase inhibitors in the treatment of pyoderma gangrenosum: case report and review

Use of biologic therapies in the management of pyoderma gangrenosum: a systematic review